Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 27Neoplasm Metastasis 9Stomach Neoplasms 7Ovarian Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Esophageal Neoplasms 3Endometrial Neoplasms 3Sarcoma 2Salivary Gland Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2HER2-positive Gastric Cancer 2Carcinoma, Renal Cell 2Brain Neoplasms 2Advanced Solid Tumor 2Advanced Breast Cancer 2Adenocarcinoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1

Interventions

Drug Therapy 2trastuzumab deruxtecan 1spartalizumab 1sacituzumab govitecan 1Radiotherapy 1Nivolumab 1Interleukin-2 1Fecal Microbiota Transplantation 1Docetaxel 1Cyclophosphamide 1Cisplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Drug-Related Side Effects and Adverse Reactions × trastuzumab deruxtecan × Clear all
NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Recruiting
70 enrolled
Breast

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon ⚡